Immuneering (IMRX) Corporation announced the formation of its Pancreatic Cancer Advisory Board. The Company’s Pancreatic Cancer Advisory Board includes the following members: Tanios Bekaii-Saab, M.D., Vincent Chung, M.D., FACP, Shubham Pant, M.D., Jordan Berlin, M.D., FASCO.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering to present data from Phase 2a trial of IMM-1-104 in early January
- Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
- Immuneering granted FDA Fast Track designation for IMM-1-104
- Immuneering Corp. Reports Q3 Loss, Highlights Progress
- Immuneering reports Q3 EPS (49c), consensus (55c)